Background. It has been demonstrated that alkylating agents such as cyclophosphamide (CYP) are effective in reducing the risk of relapse in frequently relapsing (FRNS) and steroid-dependent nephrotic syndrome (SDNS). Little is known about prognostic factors in SDNS and FRNS treated by CYP. The objectives of this study are to determine long-term outcomes and factors associated with sustained remission in these patients. Methods. We retrospectively studied the data from 143 children (104 boys) with SDNS and FRNS treated with CYP in six centres over 15 years. Relapse-free survival was estimated by Kaplan-Meier method. The determinants of long-term remission were assessed by univariate and multivariate analyses using Cox proportional hazard models. Results. Median age at diagnosis was 3.7 years (interquartile range: IQR 2.3-5.9), and median follow-up was 7.8 years (IQR 4.0-11.8). CYP treatment was introduced after a median time of 1.7 years (IQR 0.7-5.9) after diagnosis. Patients received a median cumulative dose of 168 mg/kg (IQR 157-197) body weight. Relapse-free survival was 65%, 44%, 27% and 13% after 6 months, 1 year, 2 years and 5 years, respectively. In multivariate analysis, sustained remission >2 years was associated with age at treatment >5 years (P = 0.02) and cumulative dose of CYP >170 mg/kg (P = 0.02). Frequently relapsing versus steroid-dependent status and female gender were predictors of borderline significance. Height and body mass index standard deviation score were significantly influenced by CYP treatment. Conclusion. In our study, long-term efficacy of cyclophosphamide in steroid-responsive nephrotic syndrome is disappointing. Further well-designed trials are required to evaluate the efficacy of other steroid-sparing agents.
Introduction
Idiopathic nephrotic syndrome (NS) is the most frequent glomerular disease in childhood, with reported incidence varying from two to seven cases per 100,000 children [1] . Most patients are steroid responsive, achieving complete remission, but about 70% will relapse [2] . Of those, 60% relapse frequently or become steroid-dependent [2] . In patients with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS), side effects of steroids can occur, including growth failure, obesity, hypertension, osteoporosis and ocular complications. To reduce the degree of steroid dependency and avoid steroid toxicity, several non-steroid immunosuppressive agents have been proposed to treat these children [3] .
Cyclophosphamide (CYP) has been used since the early 1970s in the treatment of NS [4] , especially in individuals with marked steroid side effects. CYP has been known to reduce relapse frequency and to induce long-term remission. According to a meta-analysis including 102 children from three trials performed in children with relapsing steroid-sensitive NS, CYP in comparison with prednisone alone results in a significant decreased risk of relapse at 6-12 months (relative risk 0.44, CI 0.26-0.73) [5] . However, the use of daily CYP treatment has been associated with bone marrow depression, increased susceptibility to in-fections, haemorrhagic cystitis, alopecia and, in long term, sterility or increased risk of malignancy [6] . These side effects of CYP have led to the use of other steroid-sparing agents such as levamisole (Lev) [7] , cyclosporine (CsA) [8, 9] , mycophenolate mofetil (MMF) [10, 11] and, more recently, rituximab [12] . Due to the potential nephrotoxicity of CsA and the lack of evidence for efficacy of Lev, MMF and rituximab, CYP is still commonly used as the first-line non-steroid agent in SDNS and FRNS. In a meta-analysis, the remission rate of NS at 5 years after CYP was found to be rather low, ranging from 24% to 36% [6] . Some potential determinants like steroid dependency, age <5.5 years at diagnosis, male sex and absence of leukopaenia during treatment have been associated with a lower efficacy of CYP [13] . However, limited data exist about its long-term efficacy, and identification of a target population who may benefit from CYP treatment remains a challenge for paediatric nephrologists. The objectives of this study are to evaluate the long-term results of CYP treatment and to identify parameters that might predict CYP efficacy.
Materials and methods

Study population
We performed a retrospective multicentre cohort study, including 143 children with idiopathic nephrotic syndrome according to the criteria of the International Study of Kidney Diseases in Children [1] . Patients were followed in six different French-speaking centres (Bordeaux, Limoges, Lyon, Montpellier, Tlemcen and Toulouse) and have been treated by CYP in the period 1993-2008. The recommended dose of CYP was 2 to 2.5 mg/kg/day of oral CYP over 10 to 12 weeks. The goal of the treatment was to stop corticosteroids within 2 months following the end of CYP therapy. Patients treated with another alkylating agent prior CYP treatment were excluded from the study.
Definitions
All patients were steroid responsive at initial presentation and were treated according to the guidelines of the French Society for Pediatric Nephrology [14] . Relapses were treated with prednisone 60 mg/m 2 /day until urinary remission, followed by alternate-day prednisone for 4 months. Steroid dependency was defined as at least two relapses during alternate-day treatment with prednisone or within 14 days after stopping this treatment [14] . Frequent relapses were defined as two relapses during 6 months or three relapses in 1 year. Clinical remission was defined as zero to trace albuminuria on dipstick on five consecutive days. For the analysis, we defined a sustained remission as a relapse-free period for 2 years or more since CYP treatment.
Data collection
Age at onset of disease, clinical characteristics of initial episode of NS, renal histology, time of relapses, use of other immunosuppressive treatments (Lev, MMF, CsA) and dose of prednisone before CYP introduction were recorded. Treatment duration and cumulative dose of CYP were calculated. The cumulative dose of CYP and the dose of prednisone at CYP introduction were transformed into binary variables according to the median values (i.e. 170 mg/kg and 0.75 mg/kg/day, respectively). Height and body mass index (BMI) were recorded at diagnosis, at start of CYP, at the first relapse after CYP and at last follow-up. Height and BMI were transformed into standard deviation score (SDS) according to national reference curves [15, 16] .
Statistical analyses
Data are presented as mean ± SD (standard deviation) or median and interquartile range (IQR) for continuous variables and percentages for categorical variables. Kaplan-Meier analysis was performed to estimate the relapse-free survival since the start of CYP. The end point was the time of first relapse after CYP censored at last available follow-up. Comparisons between subgroups were done using a logrank test. In order to evaluate factors associated with a sustained remission after CYP treatment, a Cox proportional hazard model was established using a backward stepwise procedure. The Wilcoxon rank sum test was used to compare the height and BMI SDS variations before and after CYP. Statistical analysis was performed using the SAS 8.2 software (SAS Institute, Carry, USA).
Results
Population characteristics
Data from 143 patients (104 boys and 39 girls) with FRNS or SDNS treated with CYP have been analysed. Median Long-term effects of CYP therapy in SDNS or FRNS 179 duration of follow-up was 7.8 years (4.0-11.8). Diagnosis was made at a median age of 3.7 years (IQR 2.3-5.9). When a renal biopsy was performed (n = 81), histological analysis showed minimal change disease, focal and segmental glomerulosclerosis and diffuse mesangial proliferation in 81%, 15% and 4% of cases, respectively. CYP was introduced after a median total number of four relapses (IQR 3-8) and a median time of 1.7 years (IQR 0.7-5.9). The median cumulative dose of CYP was 168 mg/kg (IQR 157-197). The main indication reported for CYP treatment was steroid dependency or frequent relapses in 75% of patients and steroid toxicity in 25%. Patients' characteristics are summarized in Table 1 . In 88 patients (62%), another immunosuppressive agent was used before (43%) or after (57%) treatment by CYP. CsA (n = 54) was introduced after a median time of 1.1 years (IQR 0.5-3.2) after diagnosis, whereas MMF (n = 54) was started 5.8 years (3.3-10.4) after diagnosis. Table 2 summarizes the different treatment strategies.
Relapse-free survival and factors associated with sustained remission
Median time to steroid withdrawal since CYP treatment (n = 132) was 10 months (IQR 3-34). In the subgroup of patients who had just received CYP and no other immunosuppressive drugs (n = 55), the median time to steroid withdrawal was 5 months (range 1-48). Ongoing remission after CYP was obtained in 29 of 143 patients (20.5%) after a median follow-up of 1.9 years (range 3 months to 7 years). According to Kaplan-Meier estimator, the cumulative relapse-free survival was 65% (CI 58-71), 45% (CI 35-55), 28% (CI 15-41), 13% (CI 0-26) and 11% (CI 0-22) at 6 months, 1 year, 2 years, 5 years and 10 years after treatment with CYP, respectively ( Figure 1 ). The median survival between start of CYP treatment and first relapse post CYP was 10 months (Figure 1) . In univariate analysis, the occurrence of sustained remission after CYP was not influenced by age at diagnosis (P = 0.32). Nevertheless, age <5 years at the introduction of CYP treatment was highly correlated with an increased risk of relapse (P = 0.01) (Figure 2) . The cumulative rate of remission was lower in boys than girls although not significantly (P = 0.13). Children with biopsy-proven minimal change disease had a significantly higher relapse-free survival (P = 0.02) than children with another underlying pathology. Children who were treated by CYP beyond the first year after disease onset were more likely to remain relapse-free (P = 0.02), as were children who received a cumulative dose of CYP >170 mg/kg (P = 0.02) and those with a low degree of steroid dependency (prednisone dose <0.75 mg/kg/day at time of CYP) (P = 0.02) (Figure 3) . Moreover, the median time without relapse after CYP treatment was 15 months in FRNS vs 8 months in SDNS (P = 0.10) (Figure 4 ). The order of CYP introduction before or after use of other immunosuppressive agents was not a predictor of sustained remission (P = 0.25).
As the exposure variables prednisone dose at CYP introduction and frequently relapsing vs steroid-dependent status were highly collinear, we decided to choose the variable FRNS vs SDNS for inclusion in the multivariable model because of its clinical relevance. In the final Cox multiple regression model (Table 3) , factors which remained significantly associated with sustained remission after treatment were cumulative dose of CYP >170 mg/kg (P = 0.02) and age at CYP treatment >5 years (P = 0.03). FRNS vs SDNS (P = 0.05) and female sex (P = 0.06) were predictors of sustained remission of borderline significance.
Evolution of height and body weight
Linear growth showed a significant decrease between diagnosis of nephrotic syndrome and CYP introduction, with a median decrease from 0.2 to −0.5 SDS (P < 0.01) over a median duration of 20 months ( Figure 5 ). From start of CYP treatment to the first relapse after CYP, median height increased significantly from −0.5 to −0.1 SDS (P < 0.01) over a median duration of 11 months. However, height SDS at last follow-up was not significantly different from height SDS at time of CYP ( Figure 5 ).
Median BMI increased significantly from 0.9 to 1.6 SDS (P < 0.01) between diagnosis and CYP introduction. After using CYP treatment, BMI decreased significantly to 0.9 SDS (P < 0.01) and remained stable afterwards ( Figure 6 ).
Discussion
We conducted a retrospective multicentre study describing the long-term clinical course of a large cohort of patients with NS treated with oral CYP. More than half of children experienced relapse during the first 12 months following the CYP course, and only 20% of children achieved a prolonged remission. The overall long-term success rate after CYP treatment in our study is disappointing and globally Long-term effects of CYP therapy in SDNS or FRNS 181 worse than reported in other studies [12, 17] . Vester et al. have reported a relapse-free survival of 44%, 34% and 24% at 1, 2 and 10 years after CYP in a cohort of 94 children with biopsy-proven minimal change disease [12] . In a cohort of 93 Dutch patients with biopsy-proven minimal change disease, 33 (35%) never experienced relapse after the first course of CYP [17] . It cannot be assessed, however, whether these populations and ours are comparable in terms of disease severity before CYP course. Given the potential adverse effects of CYP, more data on predictors of remission are needed to identify early those children who might benefit from this treatment. We identified several factors associated with a sustained remission. The negative impact of male gender has already been reported by others [6] . We found, as expected, that the risk of relapse was higher in the group of patients with SDNS compared with patients with FRNS before CYP course. Moreover, the use of CYP before 5 years of age was associated with a considerable risk of relapse. The relapse-free survival in this subgroup was 50% at 6 months and only 29% at 12 months after CYP, and this result remained significant after adjusting for potential confounding variables (sex, SDNS vs FRNS, cumulative dose of CYP and timing of CYP introduction). This finding suggests that CYP is of limited interest in the early years of NS when the disease activity is higher. The rate of remission was also significantly associated with a cumulative dose of CYP of >170 mg/kg. This is in contrast with a previous study showing that cumulative dose of CYP per body surface area but no per body weight was a predictor of sustained remission [13] . Yet, the dose-dependent effect of CYP does not prompt to use a high dose because of the inverse correlation between cumulative dose and spermatogenesis [18] , and the risk of definitive sterility over 200 mg/kg [5] . The systematic review of Latta et al. suggests that single courses of CYP exceeding 2 mg/kg/day during 12 weeks and repeated courses should be avoided [6] . We did not find a relationship between patient age at initial presentation and incidence of remission, whereas previous studies had suggested that early onset of disease predisposes to a lengthy [17, 19] or a more frequently relapsing course [13, 20] . Lastly, the use of another non-steroid agent before CYP treatment did not contribute to a better efficacy of CYP. Severe growth retardation related to corticosteroids effects has been widely reported in children with SDNS and FRNS [21, 22] . Catch-up growth after cessation of steroid treatment may not be constant [23] . A major indication for using immunosuppressive treatments in NS is the growth impairment associated with long-term steroid treatment. However, studies specifically investigating the effect of one immunosuppressive agent on growth and body weight in patients with SDNS or FRNS are rare [24, 25] . In a single-centre study including 60 children, CYP treatment was associated with an increase in height SDS from −0.84 ± 0.4 to −0.28 ± 0.3 [25] . In our study, the use of CYP had a mild but significant impact on growth with an increase of median height SDS from −0.5 at the start of CYP treatment to −0.1 at the first relapse after CYP. Moreover, we also observed an improvement of BMI, with a significant decrease of BMI SDS from +1.6 at the start of CYP treatment to +0.9 at the first relapse after CYP. However, the long-term risk of obesity is high with 25% of patients having a BMI over +2 SDS at last followup. Since the decrease of prednisone dose after CYP treatment has not been systematically recorded in our study, it must be assumed that the beneficial effect of CYP on growth and BMI was due to the reduction of corticosteroids. In our study, steroids should have been withdrawn within 2 months of completion of CYP. However, steroids were stopped after a median time of 10 months after start of CYP. Indeed, steroid withdrawal was achieved according to protocol in about one-third of patients; relapse occurred during CYP course or steroid decrease in one-third of patients; and steroids were not discontinued within 2 months after the end of CYP course despite no relapse in one-third of patients. This was likely to have an impact on post CYP growth, as those with early steroid withdrawal experienced better growth. Many children with SDNS or FRNS have a long-term disease course and usually receive more than one immunosuppressive agent so that exact long-term efficacy of CYP is difficult to appreciate. In that setting, determining the place of CYP among the different options for the management of steroid-sensitive nephrotic syndrome remains difficult. However, we believe that the efficacy of CYP to obtain a long-term remission might be limited, particularly in boys, aged <5 years old, with a high degree of steroid dependency. This study has some limitations. It is a retrospective multicentre study with a risk of changes in treatment modalities during time and between centres. Moreover, the patients have been identified from the units'databases so that the exhaustiveness cannot be ascertained. Thus, there is a possibility that the outcome may have been made to look worse than it actually was, as some of the most favourable cases might have been lost to follow-up. Nevertheless, we believe that this study gives important information for clinicians with its long-term follow-up and its large number of patients.
In conclusion, this study suggests that long-term efficacy of cyclophosphamide in steroid-responsive nephrotic syndrome is rather disappointing. Cyclophosphamide might not be the first-line non-steroid agent for children with frequently relapsing or steroid-dependent nephrotic syndrome. Further well-designed trials are required to evaluate the efficacy of other steroid-sparing agents. Long-term effects of CYP therapy in SDNS or FRNS 183
